Displaying 155 (all) recruiting clinical trials.
-
A PHASE 1 FIRST IN HUMAN DOSE ESCALATION AND EXPANSION MULTICENTER STUDY OF XMT- 2056 IN PARTICIPANTS WITH ADVANCED/RECURRENT SOLID TUMORS THAT EXPRESS HER2
The proposed first-in-human study of XMT-2056 will be a Phase 1, open-label study of XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing ...Phase
Interventional
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
Study DCC-3116-01-001 is a FIH study of DCC-3116 to evaluate safety and preliminary activity of DCC-3116 as monotherapy, and in combination with the mitogen activated ...Phase
Interventional
-
EVEREST-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
This is a first-in-human, seamless Phase 1/2, multicenter, open-label, nonrandomized study. This study consists of Phase 1 dose-escalation and dose-expansion portions and a Phase ...Phase
Interventional
-
A Phase 3 Randomized Placebo-Controlled Double-Blind Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type Advanced or Recurrent Endometrial Carcinoma (GOG 3083)
The purpose of this research study is to further evaluate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.Phase
Interventional
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This is a first-in-human Phase 1/2, open-label, multicenter, dose-escalation and -expansion study designed to determine the MTD of TNG260 as single agent and in ...Phase
Interventional
-
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose ...Phase
Interventional
-
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma ...Phase
Interventional
-
A Single-Arm Phase 2 Study Of Daratumumab In Previously Treated Stk11/Lkb1 Mutated Non-Small Cell Lung Cancer
This is a single arm, signal finding study of daratumumab in metastatic NSCLC patients with an STK11/LKB1 mutation. Patients will have received previous standard ...Phase
Interventional
-
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD ...Phase
Interventional
-
A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
Phase I/IB, single arm trial of Two-Fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost based on genomic classification in the ...Phase
Interventional
